Neurology Archives - Page 9 of 11

Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise

Authors: B M Heeg, J Antunes, M L Figueira, J M Jara, J Marques Teixeira, A P Palha, A Vaz Serra, E Buskens, S Caleo, C Gouveia-Pinto, B A Van Hout. Published:...

A pharmacoeconomic analysis of compliance gains on antipsychotic medications

Authors: J Damen, P O Thuresson, B Heeg, M Lothgren Published: Applied Health Economics and Health Policy, 2010 View publication Background Compliance among patients with schizophrenia is typically poor. Consequently, treatments that...

Modelling approaches: the case of schizophrenia

Authors: B M Heeg, J Damen, E Buskens, C Caleo, F de Charro, B A van Hout Published: Pharmacoeconomics, 2010 View publication Abstract Schizophrenia is a chronic disease characterized by periods of...

Mapping of the insomnia severity index and other sleep measures to EuroQol EQ-5D health state utilities

Authors: N Y Gu, M F Botteman, X Ji, C F Bell, J A Carter, B van Hout Published: Health Quality of Life Outcomes, 2011 View publication Background This study sought to...

Cost effectiveness of long-acting risperidone in Sweden

Authors: M Hensen, B Heeg, M Löthgren, B van Hout Published: European Journal of Health Economics, 2010 View publication Background In Sweden, risperidone long-acting injectable (RLAI) is generally used in a population...

Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations

Authors: J F Logman, B M Heeg, J Herlitz, B A van Hout Published: Applied Health Economics and Health Policy, 2010 View publication Background Antiplatelet therapy plays a central role in the...

Health economics of insomnia therapy: implications for policy

Authors: M F Botteman Published: Sleep Medicine, 2010 View publication Abstract Chronic primary insomnia is a major public health problem causing significant burden for those affected. Rising health care costs may cause...

Cost-effectiveness of eszopiclone for the treatment of adults with primary chronic insomnia

Authors: S J Snedecor, M F Botteman, C Bojke, K Schaefer, N Barry, A S Pickard Published: Sleep, 2010 View publication Objective To assess the cost-effectiveness of treatment with eszopiclone for chronic...

The cost-effectiveness of atypicals in the UK

Authors: B Heeg, E Buskens, M Botteman, S Caleo, M Ingham, J Damen, F de Charro, B van Hout Published: Value Health, 2010 View publication Background In 2002, the National Institute for...

News